Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8543)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Sep 10, 2015 (publication date) through Jun 11, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Diabetes
ISSN
1948-9358
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Sanchez RA, Sanabria H, Santos CL, Ramirez AJ. Incretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart disease. World J Diabetes 2015; 6(11): 1186-1197 [PMID: 26380062 DOI: 10.4239/wjd.v6.i11.1186] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v6/i11/1186.htm |
| Number | Citing Articles |
| 1 |
Francesco Paneni, Thomas F. Lüscher. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes. The American Journal of Medicine 2017; 130(6): S18 doi: 10.1016/j.amjmed.2017.04.008
|
| 2 |
Bassant Orabi, Rasha Kaddoura, Amr S. Omar, Cornelia Carr, Abdulaziz Alkhulaifi. Molecular and clinical roles of incretin-based drugs in patients with heart failure. Heart Failure Reviews 2018; 23(3): 363 doi: 10.1007/s10741-018-9702-3
|
| 3 |
Yongin Cho, Yong-ho Lee. State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis. Endocrinology and Metabolism 2022; 37(1): 38 doi: 10.3803/EnM.2022.102
|
| 4 |
Prakash Deedwania, Tushar Acharya. Cardiovascular Protection with Anti-hyperglycemic Agents. American Journal of Cardiovascular Drugs 2019; 19(3): 249 doi: 10.1007/s40256-019-00325-9
|
| 5 |
Tushar Acharya, Prakash Deedwania. Cardiovascular outcome trials of the newer anti-diabetic medications. Progress in Cardiovascular Diseases 2019; 62(4): 342 doi: 10.1016/j.pcad.2019.08.003
|
| 6 |
Gerasimos Siasos, Evanthia Bletsa, Panagiota K. Stampouloglou, Stavroula A. Paschou, Evangelos Oikonomou, Vasiliki Tsigkou, Alexios S. Antonopoulos, Manolis Vavuranakis, Dimitrios Tousoulis. Novel Antidiabetic Agents: Cardiovascular and Safety Outcomes. Current Pharmaceutical Design 2020; 26(46): 5911 doi: 10.2174/1381612826666201109110107
|
| 7 |
Yongin Cho, Eun Seok Kang. Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitor and Its Possible Cardioprotective Mechanism. Journal of Lipid and Atherosclerosis 2018; 7(1): 21 doi: 10.12997/jla.2018.7.1.21
|
| 8 |
Patricio López-Jaramillo, Eduardo Barbosa, Dora I. Molina, Ramiro Sanchez, Margarita Diaz, Paul A. Camacho, Fernando Lanas, Miguel Pasquel, José L. Accini, Carlos I. Ponte-Negretti, Luis Alcocer, Leonardo Cobos, Fernando Wyss, Weimar Sebba-Barroso, Antonio Coca, Alberto Zanchetti. Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome. Journal of Hypertension 2019; 37(6): 1126 doi: 10.1097/HJH.0000000000002072
|
| 9 |
Francesco Paneni, Thomas F. Lüscher. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes. The American Journal of Cardiology 2017; 120(1): S17 doi: 10.1016/j.amjcard.2017.05.015
|